Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
Authors:
Open Access
- 3 August 2010
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 8 (8) , 1685-1693
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placementJournal of Thrombosis and Haemostasis, 2010
- Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator‐stimulated phosphoprotein phosphorylation assayJournal of Thrombosis and Haemostasis, 2010
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2010
- Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classificationsEuropean Heart Journal, 2009
- Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent ThrombosisJACC, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary interventionEuropean Heart Journal, 2008
- CYP2C19 and Nongenetic Factors Predict Poor Responsiveness to Clopidogrel Loading dose after Coronary Stent ImplantationPharmacogenomics, 2008
- Variability in Individual Responsiveness to ClopidogrelJACC, 2007